Founded in October 2006
ArisGen addresses unresolved problems in the pharmaceutical use of peptides
and proteins.
ArisGen is focused on enhanced protein therapeutics and the non-invasive
delivery of peptides and proteins. The use of peptides and proteins as therapeutic
agents is limited by a shortage of effective means of delivery other than
injection. Peptide and protein therapeutics are further disadvantaged as
drugs if they produce an immune response and by the difficulty of achieving
high bioavailability into the systemic circulation due to enzymatic degradation.
ArisGen proposes solutions to improve protein drug delivery and therapeutic
treatment based on proteins. Other companies have already partially addressed
these problems by irreversibly binding polyethylene glycol molecules (PEG)
or other polymers to the therapeutic protein. A major disadvantage of this
method is often the attenuation of protein activity by obstruction of the
active sites.
ArisGen possesses proprietary technologies to improve peptide and protein
biopharmaceutical properties via reversible esterification as well as a
novel and innovative formulation platform technology. These techniques permit
(i) the enhancement of peptide and protein biopharmaceutical properties,
(ii) the control of drug delivery into the organism and (iii) the use of
non-invasive delivery routes for administration.
ArisGen’s proprietary platform technologies have been developed by
Dr. Paolo Botti, former Principal Scientist at Gryphon Therapeutics (S.San
Francisco, CA, USA) and Director of Synthesis at Geneprot (Geneva, Switzerland).
www.arisgen.com |
|
French
version 
